bacterial vaccines

Summary

Summary: Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.

Top Publications

  1. ncbi Identification and cloning potentially protective antigens of Coxiella burnetii using sera from mice experimentally infected with Nine Mile phase I
    G Q Zhang
    Department of Medical Microbiology and Immunology, Texas A M University System Health Science Center, College Station, Texas 77843 1114, USA
    Ann N Y Acad Sci 990:510-20. 2003
  2. ncbi Tularemia as a biological weapon: medical and public health management
    D T Dennis
    Division of Vector Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, PO Box 2087, Fort Collins, CO 80522, USA
    JAMA 285:2763-73. 2001
  3. ncbi Tularaemia: bioterrorism defence renews interest in Francisella tularensis
    Petra C F Oyston
    Dstl Porton Down, Salisbury, Wiltshire, SP4 0JQ, UK
    Nat Rev Microbiol 2:967-78. 2004
  4. ncbi Vaccination with Clostridium perfringens recombinant proteins in combination with Montanide™ ISA 71 VG adjuvant increases protection against experimental necrotic enteritis in commercial broiler chickens
    Seung I Jang
    Animal Parasitic Diseases Laboratory, Animal and Natural Resources Institute, Agricultural Research Service US Department of Agriculture, Beltsville, MD 20705, USA
    Vaccine 30:5401-6. 2012
  5. pmc A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection
    Wildaliz Nieves
    Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, USA
    Vaccine 29:8381-9. 2011
  6. pmc Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen
    Albert I Ko
    Division of Infectious Disease, Weill Medical College of Cornell University, New York, New York 10021, USA
    Nat Rev Microbiol 7:736-47. 2009
  7. ncbi Control of Mycoplasma hyopneumoniae infections in pigs
    D Maes
    Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium
    Vet Microbiol 126:297-309. 2008
  8. ncbi Progress toward development of vaccines against melioidosis: A review
    Mitali Sarkar-Tyson
    Defence Science and Technology Laboratory, Salisbury, United Kingdom
    Clin Ther 32:1437-45. 2010
  9. ncbi Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis
    Michelle Nelson
    Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK
    J Med Microbiol 53:1177-82. 2004
  10. ncbi Efficacy of a killed vaccine for the control of paratuberculosis in Australian sheep flocks
    L Reddacliff
    NSW Department of Primary Industries, PMB 8, Camden, NSW 2570, Australia
    Vet Microbiol 115:77-90. 2006

Detail Information

Publications348 found, 100 shown here

  1. ncbi Identification and cloning potentially protective antigens of Coxiella burnetii using sera from mice experimentally infected with Nine Mile phase I
    G Q Zhang
    Department of Medical Microbiology and Immunology, Texas A M University System Health Science Center, College Station, Texas 77843 1114, USA
    Ann N Y Acad Sci 990:510-20. 2003
    ..Further characterization of these proteins will provide essential information for developing novel, specific diagnostic reagents and potential subunit vaccine candidates against C. burnetii infection...
  2. ncbi Tularemia as a biological weapon: medical and public health management
    D T Dennis
    Division of Vector Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, PO Box 2087, Fort Collins, CO 80522, USA
    JAMA 285:2763-73. 2001
    ..The Working Group on Civilian Biodefense has developed consensus-based recommendations for measures to be taken by medical and public health professionals if tularemia is used as a biological weapon against a civilian population...
  3. ncbi Tularaemia: bioterrorism defence renews interest in Francisella tularensis
    Petra C F Oyston
    Dstl Porton Down, Salisbury, Wiltshire, SP4 0JQ, UK
    Nat Rev Microbiol 2:967-78. 2004
    ..This is a reflection of the increased funding of research on this pathogen, particularly in the United States...
  4. ncbi Vaccination with Clostridium perfringens recombinant proteins in combination with Montanide™ ISA 71 VG adjuvant increases protection against experimental necrotic enteritis in commercial broiler chickens
    Seung I Jang
    Animal Parasitic Diseases Laboratory, Animal and Natural Resources Institute, Agricultural Research Service US Department of Agriculture, Beltsville, MD 20705, USA
    Vaccine 30:5401-6. 2012
    ..These results suggest that vaccination with clostridial recombinant proteins, particularly NetB toxin or PFO, in combination with ISA 71 VG enhances protective immunity against experimental necrotic enteritis in broiler chickens...
  5. pmc A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection
    Wildaliz Nieves
    Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, USA
    Vaccine 29:8381-9. 2011
    ..pseudomallei that can be exploited for other intracellular respiratory pathogens, including other Burkholderia and bacteria capable of establishing persistent infection...
  6. pmc Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen
    Albert I Ko
    Division of Infectious Disease, Weill Medical College of Cornell University, New York, New York 10021, USA
    Nat Rev Microbiol 7:736-47. 2009
    ..We discuss the life cycle of the bacterium, the recent advances in our understanding and the implications for the future prevention of leptospirosis...
  7. ncbi Control of Mycoplasma hyopneumoniae infections in pigs
    D Maes
    Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium
    Vet Microbiol 126:297-309. 2008
    ..Eradication of the infection at herd level based on age-segregation and medication is possible, but there is a permanent risk for re-infections...
  8. ncbi Progress toward development of vaccines against melioidosis: A review
    Mitali Sarkar-Tyson
    Defence Science and Technology Laboratory, Salisbury, United Kingdom
    Clin Ther 32:1437-45. 2010
    ..Treatment is often unsuccessful, with infection frequently relapsing. Burkholderia pseudomallei, the etiologic agent of melioidosis, is inherently resistant to many antibiotics...
  9. ncbi Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis
    Michelle Nelson
    Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK
    J Med Microbiol 53:1177-82. 2004
    ..This study is the first time antigens protective by active immunization have been identified and suggests that polysaccharides have potential as vaccine candidates against melioidosis...
  10. ncbi Efficacy of a killed vaccine for the control of paratuberculosis in Australian sheep flocks
    L Reddacliff
    NSW Department of Primary Industries, PMB 8, Camden, NSW 2570, Australia
    Vet Microbiol 115:77-90. 2006
    ..Data from this trial enabled the registration of Gudair in Australia in 2002 and underpins the pivotal role of vaccination in the current management of OJD...
  11. ncbi Immunization with the recombinant Burkholderia pseudomallei outer membrane protein Omp85 induces protective immunity in mice
    Yu Ching Su
    School of Biosciences and Biotechnology, Faculty of Science and Technology, Universiti Kebangsaan Malaysia, 43600 UKM Bangi, Selangor Darul Ehsan, Malaysia
    Vaccine 28:5005-11. 2010
    ..pseudomallei by human polymorphonuclear cells. In conclusion, we demonstrated that B. pseudomallei Omp85 is potentially able to induce protective immunity against melioidosis...
  12. ncbi Brucellosis vaccines: past, present and future
    Gerhardt G Schurig
    Center for Molecular Medicine and Infectious Diseases, Virginia Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA
    Vet Microbiol 90:479-96. 2002
    ..Limited success has been obtained with these or with DNA vaccines encoding known protective antigens in experimental models and further work is indicated...
  13. pmc ATP-binding cassette transporters are targets for the development of antibacterial vaccines and therapies
    Helen S Garmory
    Department of Biomedical Sciences, Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, United Kingdom
    Infect Immun 72:6757-63. 2004
  14. pmc Vaccine assembly from surface proteins of Staphylococcus aureus
    Yukiko K Stranger-Jones
    Department of Microbiology, University of Chicago, 920 East 58th Street, Chicago, IL 60637, USA
    Proc Natl Acad Sci U S A 103:16942-7. 2006
    ..When assembled into a combined vaccine, the four surface proteins afforded high levels of protection against invasive disease or lethal challenge with human clinical S. aureus isolates...
  15. pmc Recombinant Bacillus subtilis expressing the Clostridium perfringens alpha toxoid is a candidate orally delivered vaccine against necrotic enteritis
    Tran H Hoang
    School of Biological Sciences, Royal Holloway, University of London, Egham, Surrey TW20 0EX, United Kingdom
    Infect Immun 76:5257-65. 2008
    ..Existing use of spores as competitive exclusion agents in animal feeds supports their use as a potentially economical and heat-stable vaccine for the poultry industry...
  16. pmc Immunity to murine chlamydial genital infection
    Richard P Morrison
    Department of Microbiology, Montana State University, Bozeman 59717, USA
    Infect Immun 70:2741-51. 2002
  17. pmc Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A
    S J Ward
    Microbial Pathogenicity Research Group, Department of Microbiology, St Bartholomew s and the Royal London School of Medicine and Dentistry, London EC1A 7BE, United Kingdom
    Infect Immun 67:2145-52. 1999
    ..The availability of live attenuated Salmonella typhi for human use may allow the development of a multivalent mucosal vaccine against CDAD, tetanus, and typhoid...
  18. pmc Antigenic and genetic heterogeneity of Borrelia burgdorferi populations transmitted by ticks
    J Ohnishi
    Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA
    Proc Natl Acad Sci U S A 98:670-5. 2001
    ..burgdorferi transmission. Implicit in our model is the concept that tick transmission converts a homogeneous spirochete population into a heterogeneous population that is poised to infect the mammalian host...
  19. pmc Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes
    Sharon J Peacock
    Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    PLoS Negl Trop Dis 6:e1488. 2012
    ..Here, we discuss target populations for vaccination, consider the cost-benefit of different vaccination strategies and review potential vaccine candidates...
  20. pmc Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy
    Hua Shen
    Institute for Biological Sciences, National Research Council Canada, Ottawa, Ontario, Canada
    PLoS ONE 5:e13349. 2010
    ..A live vaccine strain (LVS) derived from the less virulent holarctica subspecies confers incomplete protection against aerosol challenge with subsp. tularensis. Moreover, correlates of protection have not been established for LVS...
  21. pmc Antigen selection based on expression levels during infection facilitates vaccine development for an intracellular pathogen
    Claudia Rollenhagen
    Department of Molecular Biology, Max Planck Institute for Infection Biology, Schumannstrasse 21 22, D 10117 Berlin, Germany
    Proc Natl Acad Sci U S A 101:8739-44. 2004
    ..In conclusion, we have established a rationale and an experimental strategy that will substantially facilitate vaccine development for Salmonella and possibly other intracellular pathogens...
  22. ncbi Lipopolysaccharide from Burkholderia thailandensis E264 provides protection in a murine model of melioidosis
    Sarah A Ngugi
    Dstl Porton Down, Salisbury, Wiltshire SP4 0JQ, UK
    Vaccine 28:7551-5. 2010
    ..Similar protection levels were observed when either LPS was used as the immunogen. This data suggests that B. thailandensis LPS has the potential to be used as part of a subunit based vaccine against pathogenic B. pseudomallei...
  23. ncbi Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic back
    Wangxue Chen
    National Research Council Canada, Institute for Biological Sciences, Ottawa, Ont, Canada K1A 0R6
    Vaccine 21:3690-700. 2003
    ..tularensis. Neither mouse strain immunized with LVS was able to resist aerosol challenge with Type A F. tularensis, and only immunized BALB/c mice withstood exposure to aerosols of Type B F. tularensis...
  24. pmc The Burkholderia pseudomallei Δasd mutant exhibits attenuated intracellular infectivity and imparts protection against acute inhalation melioidosis in mice
    Michael H Norris
    Department of Microbiology, University of Hawaii at Manoa, Manoa, HI, 96822, USA
    Infect Immun 79:4010-8. 2011
    ..Thus, the B. pseudomallei Δasd mutant may be a promising live attenuated vaccine strain and a biosafe strain for consideration of exclusion from the select agent list...
  25. ncbi Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity
    D G Brockstedt
    Cerus Corporation, 2411 Stanwell Drive, Concord, California 94520, USA
    Nat Med 11:853-60. 2005
    ..Microbial KBMA vaccines used either as a recombinant vaccine platform or as a modified form of the pathogen itself may have broad use for the treatment of infectious disease and cancer...
  26. ncbi Francisella tularensis: unravelling the secrets of an intracellular pathogen
    Petra C F Oyston
    Biomedical Sciences, Dstl Porton Down, Salisbury, Wiltshire SP4 0JQ, UK
    J Med Microbiol 57:921-30. 2008
    ..tularensis pathogenicity, and will facilitate the development of a vaccine to protect against infection...
  27. pmc Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria
    Sukumar Pal
    Department of Pathology and Laboratory Medicine, Medical Sciences I, Room D440, University of California, Irvine, Irvine, CA 92697 4800, USA
    Infect Immun 73:8153-60. 2005
    ..05). In conclusion, immunization with a purified preparation of the MOMP is as effective as vaccination with viable C. trachomatis in eliciting a protective immune response against a genital challenge in mice...
  28. pmc Staphylococcus aureus capsular polysaccharides
    Katherine O'Riordan
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Microbiol Rev 17:218-34. 2004
    ..aureus vaccine. The genetics and mechanisms of capsule biosynthesis are complex, and much work remains to enhance our understanding of capsule biosynthesis and its regulation...
  29. ncbi Lung CD4-CD8- double-negative T cells are prominent producers of IL-17A and IFN-gamma during primary respiratory murine infection with Francisella tularensis live vaccine strain
    Siobhán C Cowley
    Division of Bacterial, Parasitic and Allergenic Products, Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, U S Food and Drug Administration, Rockville, MD 20852, USA
    J Immunol 184:5791-801. 2010
    ....
  30. ncbi Polysaccharides and virulence of Burkholderia pseudomallei
    M Sarkar-Tyson
    Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK
    J Med Microbiol 56:1005-10. 2007
    ..However, immunization with killed polysaccharide mutant strains conferred different degrees of protection, demonstrating the immunological importance of the polysaccharide clusters on the surface of B. pseudomallei...
  31. pmc Nonviable Burkholderia mallei induces a mixed Th1- and Th2-like cytokine response in BALB/c mice
    Kei Amemiya
    Pathogenesis and Immunology Branch, Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702, USA
    Infect Immun 70:2319-25. 2002
    ..This may be the reason for the inability of the B. mallei cells that were examined as candidate vaccines to protect the mice from a live challenge...
  32. pmc Identification of an essential Francisella tularensis subsp. tularensis virulence factor
    Aiping Qin
    Department of Medicine, University of Virginia, Charlottesville, Virginia 22908, USA
    Infect Immun 77:152-61. 2009
    ..These experiments identified the FTT1103 protein as an essential virulence factor and also demonstrated the feasibility of creating defined attenuated vaccines based on a type A strain...
  33. pmc Susceptibility to secondary Francisella tularensis live vaccine strain infection in B-cell-deficient mice is associated with neutrophilia but not with defects in specific T-cell-mediated immunity
    C M Bosio
    Laboratory of Mycobacteria, Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics, Evaluation, and Research, Food and Drug Administration, Rockville, Maryland 20852, USA
    Infect Immun 69:194-203. 2001
    ..The neutrophilia was directly associated with B cells, since BKO mice reconstituted with naive B cells prior to a secondary challenge with LVS had decreased bacterial loads and neutrophils in the spleen and survived...
  34. pmc The terminal portion of leptospiral immunoglobulin-like protein LigA confers protective immunity against lethal infection in the hamster model of leptospirosis
    Everton F Silva
    Gonçalo Moniz Research Centre, Oswaldo Cruz Foundation, Brazilian Ministry of Health, Salvador, Brazil
    Vaccine 25:6277-86. 2007
    ..These findings indicate that the carboxy-terminal portion of LigA is an immunoprotective domain and may serve as a vaccine candidate for human and veterinary leptospirosis...
  35. pmc Essential protective role attributed to the surface lipoproteins of Borrelia burgdorferi against innate defences
    Qilong Xu
    Department of Pathobiological Sciences, Louisiana State University, Baton Rouge, LA 70803, USA
    Mol Microbiol 69:15-29. 2008
    ..Taken together, the study demonstrated that the surface lipoproteins provide B. burgdorferi with an essential protective function against host innate elimination...
  36. pmc Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis
    Shite Sebastian
    Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115, USA
    Vaccine 27:597-605. 2009
    ..tularensis and provide important insight into the development of a safer vaccine effective against infections caused by clinical type A and B strains of F. tularensis...
  37. ncbi A specific role for B cells in the generation of CD8 T cell memory by recombinant Listeria monocytogenes
    Hao Shen
    Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Immunol 170:1443-51. 2003
    ..Elucidation of factors that regulate the death phase may allow us to manipulate this process to increase the level of immunological memory and thus, vaccine efficacy...
  38. pmc Outer surface protein A protects Lyme disease spirochetes from acquired host immunity in the tick vector
    James M Battisti
    Rocky Mountain Laboratories, NIAID, NIH, 903 S 4th Street, Hamilton, MT 59840, USA
    Infect Immun 76:5228-37. 2008
    ..We conclude that OspA serves a critical antibody-shielding role during vector blood meal uptake from immune hosts and is not required for persistence in the tick vector...
  39. ncbi Temporal regulation of outer surface proteins of the Lyme-disease spirochaete Borrelia burgdorferi
    T G Schwan
    Laboratory of Human Bacterial Pathogenesis, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 903 South 4th Street, Hamilton, MT 59840, USA
    Biochem Soc Trans 31:108-12. 2003
    ..Future experiments in ticks with mutant spirochaetes that lack these proteins should clarify the speculative functions currently given to these proteins...
  40. ncbi Vaccination against paratuberculosis
    Valérie Rosseels
    WIV Pasteur Institute Brussels, Laboratory of Mycobacterial Immunology, 642 Engelandstraat, B1180 Brussels, Belgium
    Expert Rev Vaccines 7:817-32. 2008
    ..It provides an overview of the existing MAP vaccines and comments on the development of second-generation subunit vaccines based on new technologies...
  41. ncbi Immune responses in mice to Mycobacterium avium subsp. paratuberculosis following vaccination with a novel 74F recombinant polyprotein
    Li Hsuen Chen
    College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
    Vaccine 26:1253-62. 2008
    ..Results of this study indicated that immunization of mice with Map74F protected mice against MAP infection...
  42. ncbi Variable protection after vaccination of broiler chickens against necrotic enteritis using supernatants of different Clostridium perfringens strains
    A Lanckriet
    Department of Pathology, Bacteriology and Avian Diseases, Research Group Veterinary Public Health and Zoonoses, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, Merelbeke, Belgium
    Vaccine 28:5920-3. 2010
    ..Our results indicate that the protective characteristics of the supernatants are not solely based on the presence of NetB or alpha toxin...
  43. pmc Evaluation of the trimeric autotransporter Ata as a vaccine candidate against Acinetobacter baumannii infections
    Leticia V Bentancor
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Infect Immun 80:3381-8. 2012
    ..The ability of Ata to engender anti-adhesive, bactericidal, opsonophagocytic, and protective antibodies validates its potential use as an antigenic target against MDR A. baumannii infections...
  44. ncbi Safety and efficacy of a maternal vaccine for the passive protection of broiler chicks against necrotic enteritis
    C F Crouch
    Intervet Schering Plough Animal Health, Walton Manor, Walton, Milton Keynes, UK
    Avian Pathol 39:489-97. 2010
    ..These results indicate that, under commercial conditions, maternal vaccination with Netvax™ can help to control losses related to necrotic enteritis...
  45. ncbi Gene expression profiling in naïve and vaccinated rainbow trout after Yersinia ruckeri infection: insights into the mechanisms of protection seen in vaccinated fish
    Nor Omaima Harun
    Scottish Fish Immunology Research Centre, University of Aberdeen, Institute of Biological and Environmental Sciences, Tillydrone Avenue, Aberdeen AB24 2TZ, Scotland, UK
    Vaccine 29:4388-99. 2011
    ..Thus, it is possible that different types of adaptive responses are on-going within the vaccinated fish during infection with Y. ruckeri, potentially affected by the site and stage of infection...
  46. pmc Evaluation of two mutants of Mycobacterium avium subsp. paratuberculosis as candidates for a live attenuated vaccine for Johne's disease
    Kun Taek Park
    Department of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, WA 99164, United States
    Vaccine 29:4709-19. 2011
    ..The mutant also elicited an immune response that limited colonization by challenge wild type Map. The findings show the relA mutant is a good candidate for development of a live attenuated vaccine for Johne's disease...
  47. pmc Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections
    Annalisa Nuccitelli
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 108:10278-83. 2011
    ..In addition, this work describes a template procedure that can be followed to develop vaccines against other bacterial pathogens...
  48. pmc Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia
    Anthony J Hickey
    Albany Medical College, Center for Immunology and Microbial Disease, Albany, NY 12208, USA
    Vaccine 29:6941-7. 2011
    ..tularensis; however, the findings demonstrate proof of principle that an immune response generated against a component of a subunit vaccine is protective against lethal respiratory and intradermal tularemia...
  49. ncbi Partial protection against chlamydial reproductive tract infection by a recombinant major outer membrane protein/CpG/cholera toxin intranasal vaccine in the guinea pig Chlamydia caviae model
    Dean W Andrew
    Infectious Diseases Program, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Brisbane 4059, Australia
    J Reprod Immunol 91:9-16. 2011
    ..This data demonstrates the value of using the guinea pig model to evaluate potential chlamydial vaccines for protection against infection and disease pathology caused by C. trachomatis in the female reproductive tract...
  50. ncbi Protection against Acinetobacter baumannii infection via its functional deprivation of biofilm associated protein (Bap)
    Yaser Fattahian
    Department of Biology, Shahed University, Tehran Qom Express Way, Opposite Imam Khomeini s Shrine, Tehran 3319118651, Iran
    Microb Pathog 51:402-6. 2011
    ..Immunodominant region of Bap possesses target sites for a protective humoral immune response to A. baumannii. This seems to be a conserved region erecting efficacy of Bap as an appropriate vaccine candidate...
  51. pmc Efficacy of two vaccine formulations against contagious bovine pleuropneumonia (CBPP) in Kenyan indigenous cattle
    Isabel Nkando
    Kenya Agricultural Research Institute, Veterinary Research Centre, P O Box 32, 00902 Kikuyu, Kenya
    Res Vet Sci 93:568-73. 2012
    ..Because of its longer half life after reconstitution, the modified vaccine might be preferred in field situations where the reconstituted vaccine is likely not to be administered immediately...
  52. pmc Protective immunity against mouse upper genital tract pathology correlates with high IFNγ but low IL-17 T cell and anti-secretion protein antibody responses induced by replicating chlamydial organisms in the airway
    Chunxue Lu
    Department of Microbiology and Immunology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Vaccine 30:475-85. 2012
    ..These observations have provided important information on how to develop subunit vaccines for inducing protective immunity against urogenital infection with Chlamydia trachomatis organisms...
  53. pmc Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case
    Giuliano Bensi
    Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy
    Mol Cell Proteomics 11:M111.015693. 2012
    We propose an experimental strategy for highly accurate selection of candidates for bacterial vaccines without using in vitro and/or in vivo protection assays...
  54. pmc Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity
    Richard Malley
    Division of Infectious Diseases, Department of Medicine, Children s Hospital Boston and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 109:3623-7. 2012
    ..Such constructs induce accelerated clearance when given intranasally and induce both immune mechanisms when injected. The defined composition permits analysis of structure-function activity...
  55. pmc Identification of CD4+ T cell epitopes in C. burnetii antigens targeted by antibody responses
    Chen Chen
    Department of Microbial and Molecular Pathogenesis, Texas A and M Health Science Center, College Station, Texas, United States of America
    PLoS ONE 6:e17712. 2011
    ..This suggests that a complete map of CD4(+) response targets in PI-WCV vaccinated mice will likely include antigens against which no antibody responses are made...
  56. pmc Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+
    Hong Yu
    British Columbia Centre for Disease Control, Vancouver, BC, Canada
    Infect Immun 78:2272-82. 2010
    ....
  57. pmc Identification of Francisella tularensis live vaccine strain CuZn superoxide dismutase as critical for resistance to extracellularly generated reactive oxygen species
    Amanda A Melillo
    Center for Immunology and Microbial Disease, MC 151, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208, USA
    J Bacteriol 191:6447-56. 2009
    ..To conclude, this study demonstrates that SodB and SodC act to confer protection against host-derived oxidants and contribute to intramacrophage survival and virulence of F. tularensis in mice...
  58. ncbi Protective efficacy of heat-inactivated B. thailandensis, B. mallei or B. pseudomallei against experimental melioidosis and glanders
    Mitali Sarkar-Tyson
    Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire, SP4 OJQ, UK
    Vaccine 27:4447-51. 2009
    ..These studies indicate the longer term potential for heat-inactivated bacteria to be developed as vaccines against melioidosis and glanders...
  59. pmc Immunogenic Burkholderia pseudomallei outer membrane proteins as potential candidate vaccine targets
    Yuka Hara
    Malaysia Genome Institute, UKM MTDC Smart Technology Centre, Bangi, Selangor, Malaysia
    PLoS ONE 4:e6496. 2009
    ..There is no vaccine towards the bacterium available in the market, and the efficacy of many of the bacterium's surface and secreted proteins are currently being evaluated as vaccine candidates...
  60. ncbi A multi-subunit chlamydial vaccine induces antibody and cell-mediated immunity in immunized koalas (Phascolarctos cinereus): comparison of three different adjuvants
    Alison J Carey
    Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, QLD, Australia
    Am J Reprod Immunol 63:161-72. 2010
    ..Little is known about the immune response in koalas, or the safety of commonly used adjuvants for induction of protective systemic and mucosal immunity...
  61. ncbi Identification of immunogenic proteins from Burkholderia cepacia secretome using proteomic analysis
    Vanitha Mariappan
    Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
    Vaccine 28:1318-24. 2010
    ..Eighteen of these immunogenic proteins which reacted with all three antibodies were identified and might be potential molecules as a diagnostic marker or a putative candidate vaccine against B. cepacia infections...
  62. pmc Directed mutagenesis of the Rickettsia prowazekii pld gene encoding phospholipase D
    Lonnie O Driskell
    Department of Microbiology and Immunology, University of South Alabama College of Medicine, Mobile, 36688 0002, USA
    Infect Immun 77:3244-8. 2009
    ..This study demonstrates the feasibility of generating site-directed rickettsial gene mutants, providing a new tool for understanding rickettsial biology and furthering advances in the prevention of epidemic typhus...
  63. ncbi Persistence of mucosal and systemic immune responses following sublingual immunization
    Donatella R M Negri
    Department of Infectious, Parasitic and Immune Mediated Diseases, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    Vaccine 28:4175-80. 2010
    ....
  64. ncbi Canine leptospirosis--do we have a problem?
    Geneviève André-Fontaine
    Ecole Nationale Veterinaire de Nantes, Bacteriologie Medicale et Moleculaire des Leptospires B2ML, Route de Gachet, BP 40706, 44307 Nantes Cedex 03, France
    Vet Microbiol 117:19-24. 2006
    ..In a survey on 98 ill cats, 48% were positive in microagglutination test (MAT) to Leptospira spp., showing that this infection is also frequent in the feline species...
  65. ncbi Leptospira and leptospirosis
    Ben Adler
    Australian Research Council Centre of Excellence in Structural and Functional Microbial Genomics, Monash University, Clayton, Australia
    Vet Microbiol 140:287-96. 2010
    ..However, the recent development of defined mutagenesis systems for Leptospira heralds the potential for gaining a much improved understanding of pathogenesis in leptospirosis...
  66. doi Mannheimia haemolytica and bovine respiratory disease
    J A Rice
    Dow AgroSciences, Indianapolis, IN, USA
    Anim Health Res Rev 8:117-28. 2007
    ..haemolytica pneumonia. Effective control of M. haemolytica pneumonia is likely to require a combination of more definitive diagnosis, efficacious vaccines, therapeutic intervention and improved management practices...
  67. pmc An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain
    Chandra Shekhar Bakshi
    Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA
    Vaccine 26:5276-88. 2008
    ..Collectively, this study describes an improved live vaccine candidate against respiratory tularemia that has an attenuated virulence and enhanced protective efficacy than the LVS...
  68. ncbi Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- depende
    J Wayne Conlan
    National Research Council Canada, Institute for Biological Sciences, Ottawa, Ont, Canada K1A 0R6
    Vaccine 23:2477-85. 2005
    ..Further, understanding of how inhaled LVS elicits local cell-mediated protective immunity will be critical for devising improved vaccines against pulmonary tularemia...
  69. ncbi Analysis of peptide mimotopes of Burkholderia pseudomallei exopolysaccharide
    Joseph B Legutki
    Department of Microbiology, The Ohio State University, 484 W 12th Ave Rm 376, Columbus, OH 43210, United States
    Vaccine 25:7796-805. 2007
    ..00 days over the 2.18 days afforded by immunization with thyroglobulin alone. This mimotope may be of use in developing an antibody response against B. pseudomallei exopolysaccharide...
  70. pmc Comparison of the abilities of different attenuated Salmonella typhimurium strains to elicit humoral immune responses against a heterologous antigen
    S J Dunstan
    Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia
    Infect Immun 66:732-40. 1998
    ..typhimurium strain...
  71. pmc IFN-β mediates suppression of IL-12p40 in human dendritic cells following infection with virulent Francisella tularensis
    Timothy J Bauler
    Immunity to Pulmonary Pathogens Section, Laboratory of Intracellular Parasites Rocky Mountain Laboratories National Institute of Allergy and Infectious Disease National Institutes of Health, Hamilton, MT 59840, USA
    J Immunol 187:1845-55. 2011
    ..Together, these data demonstrated a novel mechanism by which virulent bacteria, in contrast to attenuated strains, modulate human cells to cause disease...
  72. pmc Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans
    H M El Sahly
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States
    Vaccine 27:4905-11. 2009
    ....
  73. ncbi Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations
    Anders Sjostedt
    Department of Clinical Bacteriology, Clinical Microbiology, Umea University, SE 901 85 Umea, Sweden
    Ann N Y Acad Sci 1105:1-29. 2007
    ..This article summarizes, predominantly with a historical perspective, the epidemiology and clinical manifestations of tularemia and the physiology of F. tularensis...
  74. ncbi Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid
    D M Granoff
    Chiron Vaccines, Emeryville, CA 94608, USA
    J Immunol 160:5028-36. 1998
    ..These Abs may be useful for the identification of molecular mimetics capable of eliciting protective Abs specific to the bacteria, without the risk of evoking autoimmune disease...
  75. ncbi Prevention of Coxiella burnetii shedding in infected dairy herds using a phase I C. burnetii inactivated vaccine
    Raphaël Guatteo
    Ecole Nationale Veterinaire de Nantes, UMR 1300 Bio Agression, Epidémiologie et Analyse de Risque, F 44307 Nantes, France
    Vaccine 26:4320-8. 2008
    ..e. at least the heifers. The vaccination of the dairy cows should be performed when the within-herd seroprevalence is low, i.e. in herds where the infection has not spread widely yet...
  76. pmc Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1
    William M Gwinn
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Vaccine 28:6901-14. 2010
    ....
  77. pmc Reintroduction of two deleted virulence loci restores full virulence to the live vaccine strain of Francisella tularensis
    Emelie Salomonsson
    FOI Swedish Defence Research Agency, Division of CBRN Defence and Security, Umea, Sweden
    Infect Immun 77:3424-31. 2009
    ..The identification of the two attenuating deletion events could facilitate the licensing of LVS for use in humans...
  78. pmc Human health benefits from livestock vaccination for brucellosis: case study
    Felix Roth
    Swiss Centre for International Health, Swiss Tropical Institute, Basle, Switzerland
    Bull World Health Organ 81:867-76. 2003
    ..To estimate the economic benefit, cost-effectiveness, and distribution of benefit of improving human health in Mongolia through the control of brucellosis by mass vaccination of livestock...
  79. ncbi Effect of vaccination with phase I and phase II Coxiella burnetii vaccines in pregnant goats
    Nathalie Arricau-Bouvery
    INRA, Pathologie Infectieuse et Immunologie, F 37380 Nouzilly, France
    Vaccine 23:4392-402. 2005
    ..Phase I vaccine was effective and dramatically reduced both abortion and excretion of bacteria in the milk, vaginal mucus and feces. In contrast, the phase II vaccine did not affect the course of the disease or excretion...
  80. pmc Recombinant attenuated Salmonella enterica serovar typhimurium expressing the carboxy-terminal domain of alpha toxin from Clostridium perfringens induces protective responses against necrotic enteritis in chickens
    Bereket Zekarias
    The Biodesign Institute, Center for Infectious Diseases and Vaccinology, Arizona State University, 1001 S McAllister, Tempe, AZ 85287 5401, USA
    Clin Vaccine Immunol 15:805-16. 2008
    ..RASV-immunized chickens had reduced intestinal mucosal pathology after challenge with virulent C. perfringens. These results indicate that oral RASV expressing an alpha toxin C-terminal peptide induces protective immunity against NE...
  81. ncbi Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortal
    G R Gunn
    Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Immunol 167:6471-9. 2001
    ..These studies demonstrate the complexity of L. monocytogenes-mediated tumor immunotherapy targeting the human tumor Ag, HPV-16 E7...
  82. pmc Current status of veterinary vaccines
    Els N T Meeusen
    Animal Biotechnology Research Laboratories, Department of Physiology, Building 13F, Monash University, Clayton, Victoria 3800, Australia
    Clin Microbiol Rev 20:489-510, table of contents. 2007
    ..The continued interaction between animals and human researchers and health professionals will be of major importance for adapting new technologies, providing animal models of disease, and confronting new and emerging infectious diseases...
  83. ncbi Actinobacillus pleuropneumoniae surface polysaccharides: their role in diagnosis and immunogenicity
    J D Dubreuil
    Groupe de Recherche sur les Maladies Infectieuses du Porc, Faculte de Medecine Veterinaire, Universite de Montreal, Saint Hyacinthe, Quebec, Canada
    Anim Health Res Rev 1:73-93. 2000
    ..Here, we review current knowledge on CPS and LPS of A. pleuropneumoniae used as diagnostic tools to monitor the infection and as immunogens for inclusion in vaccine preparations for animal protection...
  84. ncbi Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain
    Karen L Elkins
    Laboratory of Mycobacteria, Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, 1401 Rockville Pike, HFM 431, Rockville, MD 20852, USA
    Microbes Infect 5:135-42. 2003
    ..Here we review this infection model, which provides a convenient means of studying protective immune mechanisms not only for Francisella, but also for the large and important class of intracellular pathogens...
  85. ncbi Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle
    Katrin Breitbach
    Friedrich Loeffler Institute of Medical Microbiology, Ernst Moritz Arndt University Greifswald, Martin Luther Str 6, 17489 Greifswald, Germany
    Trans R Soc Trop Med Hyg 102:S89-94. 2008
    ..Further studies are required to analyze the precise nature of the immune response induced by the various live attenuated vaccines with different protective potential...
  86. pmc Host immunity in the protective response to vaccination with heat-killed Burkholderia mallei
    Gregory C Whitlock
    Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA
    BMC Immunol 9:55. 2008
    ..We performed initial cell, cytokine and complement depletion studies to investigate the possible role of these effectors in response to vaccination with heat-killed Burkholderia mallei in a susceptible BALB/c mouse model of infection...
  87. pmc Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis
    Deepak B Rawool
    Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA
    J Immunol 180:5548-57. 2008
    ..tularensis, a category A biothreat agent. In summary, these studies show for the first time the use of FcRs as a highly effective vaccination strategy against a highly virulent mucosal intracellular pathogen...
  88. ncbi Efficacy of vaccines against bacterial diseases in swine: what can we expect?
    Freddy Haesebrouck
    Department of Pathology, Bacteriology and Poultry Diseases, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium
    Vet Microbiol 100:255-68. 2004
    ..As an example, vaccination against Salmonella enterica serotype Typhimurium is discussed...
  89. pmc The continuing challenges of leprosy
    D M Scollard
    Laboratory Research Branch, National Hansen s Disease Programs, LSU SVM, Skip Bertman Dr, Baton Rouge, LA 70803, USA
    Clin Microbiol Rev 19:338-81. 2006
    ..In nearly all of these areas, however, leprosy remains poorly understood compared to other major bacterial diseases...
  90. ncbi Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus
    Stefania Bambini
    Novartis V and D, Via Fiorentina 1, 53100 Siena, Italy
    Vaccine 27:2794-803. 2009
    ..Sequencing each gene in the different strains will be important to evaluate antigen conservation and assortment and to allow a future prediction of potential vaccine coverage...
  91. ncbi Colonization factors of human enterotoxigenic Escherichia coli (ETEC)
    W Gaastra
    Dept of Bacteriology, Utrecht University, The Netherlands
    Trends Microbiol 4:444-52. 1996
    ..The ability of ETEC to adhere to the intestinal epithelium of the host is an important virulence determinant, and adhesion is mediated by proteinaceous surface appendages called colonization factors...
  92. pmc Modulation of virulence factors in Francisella tularensis determines human macrophage responses
    Paul E Carlson
    Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Microb Pathog 42:204-14. 2007
    ..This work provides a basis for investigation of Francisella virulence factor regulation and the identification of additional factors, co-regulated with IglC, that affect macrophage responses...
  93. ncbi Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model
    Dominique Velin
    Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Gastroenterology 136:2237-2246.e1. 2009
    ..This study explores the possibility that interleukin (IL)-17 plays a role in the reduction of Helicobacter infection following vaccination of wild-type animals or in spontaneous reduction of bacterial infection in IL-10-deficient mice...
  94. ncbi Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea
    Stavros Sougioultzis
    Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, 02215, USA
    Gastroenterology 128:764-70. 2005
    ..Our aim was to examine whether the vaccine is also well tolerated and immunogenic in patients with recurrent CDAD...
  95. ncbi Vaccination of sheep against M. paratuberculosis: immune parameters and protective efficacy
    D J Begg
    Disease Research Laboratory, Department of Microbiology and Immunology, University of Otago, P O Box 56, Dunedin, New Zealand
    Vaccine 23:4999-5008. 2005
    ..Immune animals had stronger cell-mediated responses and altered proportions of CD4+, CD8+, CD25+ and B cells in blood, spleen and the gut lymphatics, than diseased animals...
  96. ncbi Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria
    K L Elkins
    Laboratory of Mycobacteria, Division of Bacterial Products, Rockville, MD 20852, USA
    J Immunol 162:2291-8. 1999
    ..These findings indicate that host innate immune responses to bacterial DNA may contribute to the induction of protective immunity to bacteria and the subsequent development of memory...
  97. ncbi Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection
    Kathryn A Skelding
    Discipline of Immunology and Microbiology, School of Biomedical Sciences, Faculty of Health, The University of Newcastle, Callaghan, NSW 2308, Australia
    Vaccine 24:355-66. 2006
    ..The best protection was obtained following IN immunization and correlated with IFNgamma production by mononuclear cells in lung-draining LN and MOMP-specific IgA in BAL...
  98. ncbi Active suppression of the pulmonary immune response by Francisella tularensis Schu4
    Catharine M Bosio
    Department of Microbiology, Immunology and Pathology, Colorado State University, Ft Collins, CO 80523, USA
    J Immunol 178:4538-47. 2007
    ..tularensis, Schu4 induced broad immunosuppression within the first few days after aerosol infection. This difference may explain the increased virulence of type A strains compared with their more attenuated counterparts...
  99. pmc Tularemia
    Jill Ellis
    Defence Science and Technology Laboratory, CBS Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom
    Clin Microbiol Rev 15:631-46. 2002
    ..tularensis. In the absence of a licensed vaccine, aminoglycoside antibiotics play a key role in the prevention and treatment of tularemia...
  100. ncbi Aerogenic vaccination with a Burkholderia mallei auxotroph protects against aerosol-initiated glanders in mice
    Ricky L Ulrich
    Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702, USA
    Vaccine 23:1986-92. 2005
    ..Thus, live attenuated strains that promote a Th1-like Ig response may serve as promising vaccine candidates against aerosol infection with B. mallei...
  101. ncbi Melioidosis
    Sharon J Peacock
    Wellcome Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Curr Opin Infect Dis 19:421-8. 2006
    ..A brief summary of studies relating to genomics and genotyping, immunology and pathogenesis is provided...

Research Grants65

  1. SUPPORT CONTRACT FOR THE NTP INTERAGENCY CENTER/VALIDATION OF ALT METHODS
    David Allen; Fiscal Year: 2009
    ..NICEATM and ICCVAM will also evaluate non-animal methods and approaches for determining the skin irritation potential of antimicrobial cleaning products...
  2. Killed But Metabolically Active Leishmania: a novel protozoan vaccine technology
    Noah Craft; Fiscal Year: 2009
    ..We and others have successfully used this technology to develop safe and effective recombinant bacterial vaccines already...
  3. Mechanisms of Immune Modulation by Probiotics
    Lijuan Yuan; Fiscal Year: 2012
    ..adjuvanticity and enhanced antigen-specific immune responses to rotavirus infection and to viral and bacterial vaccines. However, the underlying mechanism of the adjuvant effect is undefined...
  4. Apoptosis and efferocytosis: regulators of immunity to tuberculosis
    Samuel M Behar; Fiscal Year: 2013
    ..By promoting apoptotic death, we hope to increase the safety and the efficacy of attenuated bacterial vaccines. We believe that a mechanistic understanding of how pro-apoptotic vaccines induce better immunity will lead ..
  5. A novel Salmonella vaccine to protect against extra intestinal pathogenic E. coli
    Melha Mellata; Fiscal Year: 2011
    ..Moreover, if successful, the delayed-attenuated lysis system proposed can be used in any live bacterial vaccine to increase their safety and efficacy in delivering antigens. ..
  6. Recombinant Attenuated Bacterial Vaccines Against Biodefense Agents
    Roy Curtiss; Fiscal Year: 2013
    ....
  7. Mucosal live vector vaccine against recurrent Clostridium difficile infections
    James E Galen; Fiscal Year: 2013
    ..difficile antigens will be further tested for protection in mice similarly immunized with he multivalent strain and challenged orogastrically with spores from an epidemic strain of C. difficile. ..
  8. Alteration of lipid A acyl chain length in Salmonella
    Qingke Kong; Fiscal Year: 2013
    ..In an effort to reduce the potential for endotoxic effects in live bacterial vaccines,we will investigate the effects of modifying the acyl chain length in living Salmonella cells...
  9. The role of LPS-TLR4 signaling in live vaccine-induced protective responses
    Egil Lien; Fiscal Year: 2013
    ..We will use novel avirulent, immunostimulatory strains of the plague bacillus Yersinia pestis as a model system. Our results may help in the design of future vaccines against plague and other infectious diseases. ..
  10. Production of Polysaccharide-Protein Conjugates as Vaccines
    Wen Yi; Fiscal Year: 2009
    ..to develop a facile and widely applicable platform for the generation of polysaccharide (PS) conjugated anti-bacterial vaccines with particular target of E. coli O157...
  11. RECOMBINANT L MONOCYTOGENES AS AN SIV VACCINE
    Andrew Kaplan; Fiscal Year: 2000
    ..Monocytogenes vectors expressing SIV proteins; (2) evaluate the immune response of rhesus macaques infected with the recombinant Listeria vectors; and (3) assess the ability of immunization strategies to alter virus replication. ..
  12. BIOLOGICAL CONTAINMENT OF LIVE BACTERIAL VACCINES
    Roy Curtiss; Fiscal Year: 2000
    ..The strains will be tested for containment, avirulence and immunogenic attributes in vitro and after excretion. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE ..
  13. Live Attenuated Bacterial Vaccines Against Anthrax
    SIMS KOCHI; Fiscal Year: 2002
    ..The successful accomplishment of these aims will provide new anthrax vaccines with the potential to confer protective immunity by oral immunization in humans. ..
  14. PHOP/PHOQ DELETED S TYPHI VACCINE STRAINS
    Elizabeth Hohmann; Fiscal Year: 2002
    ..These studies are designed to provide novel human safety and immunogenicity data which is vital to the clinical development of live bacterial vaccine vectors. ..
  15. Development and cGMP Manufacture of a Vitrified Typhoid Vaccine
    SIMS KOCHI; Fiscal Year: 2006
    ..AVANT now has technology to preserve bacterial vaccines using a proprietary preservation process that markedly improves vaccine stability at room temperature...
  16. BACTERIAL GENETICS MOLECULAR PATHOGENESIS OF SALMONELLA
    Samuel Miller; Fiscal Year: 1993
    ..formal coursework in basic science necessary to study pathogenic bacteria and develop live attenuated bacterial vaccines. Phase I research training will be spent in the laboratory of Dr...
  17. Novel Vaccine Strategy for Listeria monocytogenes
    DARREN HIGGINS; Fiscal Year: 2007
    ..It is also envisioned that these studies will provide a foundation for the development of replication-deficient vaccine vectors against other intracellular pathogens using a similar approach. ..
  18. Genetic Passive Immunotherapy for Shiga toxin
    Julie Boyer; Fiscal Year: 2005
    ..The proposal is based on our experience in the development of Ad-based anti-bacterial vaccines and the ability of Ad vectors to deliver single chain antibodies against specific pathogens...
  19. Live Vector Vaccines Against Agents of Bioterror
    James Nataro; Fiscal Year: 2007
    ..We therefore envision a response strategy which includes live attenuated enteric bacterial vaccines. These vaccines would be very safe, and would elicit both mucosal and systemic responses...
  20. Bacterial Vaccine Antigen Discovery
    LAWRENCE PAOLETTI; Fiscal Year: 2003
    ..Findings from these studies utilizing this unique approach to vaccine antigen discovery could be directly applied to other bacterial pathogens including those on the category A bioterrorism list. ..
  21. PROTECTIVE IMMUNITY TO HUMAN IMMUNODEFICIENCY VIRUS
    Edward Mocarski; Fiscal Year: 1990
    ..In the future, vaccines developed through this Program Project will be readily tested in humans...
  22. Anti-Y. pestis Vaccination and Passive Protection
    Julie Boyer; Fiscal Year: 2007
    ..pestis based on our experience in using adenovirus (Ad) gene transfer vectors to develop anti-bacterial vaccines, and the ability of Ad vectors to code for single chain antibodies against specific antigens...
  23. DENDRITIC AND T CELLS IN ANTI-BACTERIAL lg RESPONSES
    Clifford M Snapper; Fiscal Year: 2010
    ..determine the mechanisms that distinguish anti-PS from anti-protein responses to an intact bacterium and provide novel basic immunologic insights with direct relevanceto the development of anti-bacterial vaccines.
  24. ANTI-IDIOTYPE INDUCED IMMUNITY AGAINST P. AERUGINOSA
    John Schreiber; Fiscal Year: 1992
    ..These studies will provide a model for the production of other anti-idiotypic bacterial vaccines and will increase our understanding of the regulation of the mammalian host response to PA infections...
  25. TESTING VACCINES IN CHILDREN
    Robert Belshe; Fiscal Year: 1990
    Testing of respiratory, enteric and bacterial vaccines, and epidemiology of infectious diseases in children.
  26. Acellular vaccines against Francisella tularensis
    Wayne Conlan; Fiscal Year: 2005
    ..It is expected that the findings from the proposed studies will be applicable to the development of acellular vaccines against other intracellular respiratory pathogens such as Mycobacterium tuberculosis, and Chlamydia pneumoniae. ..
  27. CHILDHOOD VACCINES AND DENTAL CARIES IMMUNITY
    Daniel Smith; Fiscal Year: 2007
    ..unreadable]..
  28. Evaluation of Anti-endotoxin Vaccine for Human Use
    Alan Cross; Fiscal Year: 2006
    ..If successful, these studies will lead to phase II and Ill studies for the prevention and treatment of sepsis. ..
  29. CYTOKINE CONTROL OF RESPIRATORY IMMUNITY
    DENNIS METZGER; Fiscal Year: 2001
    ..Thus, the application of IL-12 as a mucosal vaccine adjuvant may provide a novel approach for protection against respiratory diseases and could have immediate impact on human health. ..
  30. Neutrophil-macrophage Interactions Govern Liver Immunity
    Stephen H Gregory; Fiscal Year: 2010
    ..Consequently, they should provide valuable insights that enable the development of innovative strategies to improve treatment and prevent the devastating consequencesoften associated with septicemia and sepsis. ..
  31. FRANCISELLA TULARENSIS: INNATE RESISTANCE TO IHALATION
    Stephen Gregory; Fiscal Year: 2004
    ..abstract_text> ..
  32. Recurrent otitis media and COPD: immunity and vaccines
    Timothy Murphy; Fiscal Year: 2004
    ..The proposed studies will advance the field of vaccine development to prevent otitis media and respiratory tract infections in COPD. ..
  33. DEVELOPMENT OF A VACCINE FOR MORAXELLA CATARRHALIS
    Timothy Murphy; Fiscal Year: 2009
    ..catarrhalis surface, the identification of surface antigens expressed specifically during human infection and critical information about the human immune response to surface antigens of M. catarrhalis. ..
  34. Role of Sialidase in Pulmonary Host Defenses and Acute Lung Injury
    Alan Cross; Fiscal Year: 2010
    ..Since inhibitors of sialidase are commercially available, these studies will provide the experimental rationale for testing a new therapeutic approach to the treatment of lung injury. ..
  35. Diagnosis and Pathogenesis of Early Lyme Disease
    Allen Steere; Fiscal Year: 2007
    ..In addition, greater knowledge of spirochetal virulence and host factors associated with severe disease may allow the development of laboratory markers for patients who would benefit from more intensive treatment. ..
  36. Development of a Global GBS Vaccine
    LAWRENCE PAOLETTI; Fiscal Year: 2007
    ..This work will lead to a vaccine effective in preventing GBS diseases worldwide. ..
  37. MOLECULAR AND CELLULAR BACTERIAL PATHOGENESIS
    David Briles; Fiscal Year: 2008
    ..The MCBP advisory committee will advise the trainees in their research and training programs and in their search for a job or postdoctoral position at the completion of their MCBP training. [unreadable] [unreadable]..
  38. LYME ARTHRITIS: A NEW EPIDEMIC DISEASE
    Allen C Steere; Fiscal Year: 2010
    ..Furthermore, this work brings us closer to the long-term goal of direct comparisons of antigens in Lyme arthritis and rheumatoid arthritis synovia. ..
  39. The Upstate New York Immunology Conference
    DENNIS METZGER; Fiscal Year: 2003
    ..abstract_text> ..
  40. Early events during infection with anthrax
    Alan Cross; Fiscal Year: 2006
    ..abstract_text> ..
  41. Bacterial Vaccine Antigen Discovery
    LAWRENCE PAOLETTI; Fiscal Year: 2006
    ..Aim 2). Findings from these studies utilizing this unique approach to vaccine antigen discovery could be directly applied to other bacterial pathogens. ..
  42. SIALIC ACID MODULATION REGULATES NEUTROPHIL DIAPEDESIS
    Alan Cross; Fiscal Year: 2002
    ..These studies will define a new mechanism for a rapidly adaptable, temporally- restricted local response to inflammation. This proposal will provide new targets and additional approaches to the treatment of inflammation. ..
  43. Immunology and Microbial Disease Training Grant
    DENNIS METZGER; Fiscal Year: 2006
    ....
  44. IMMUNE RESPONSES TO SMALL INTESTINAL SUBMUCOSA
    DENNIS METZGER; Fiscal Year: 2001
    ..The results will provide important insight into the mechanisms responsible for successful xenogeneic transplantation and could lead to targeted cytokine therapies to prevent tissue rejection. ..
  45. INTERFERON Y MEDIATES ANTI E COLI DEFENSES AND SEPSIS
    Alan Cross; Fiscal Year: 2001
    ..The demonstration of a spectrum of responses to LPS in these studies may identify the earliest changes in cytokine responses that predict the development of sepsis. ..
  46. Genetic Determinants of Anaplasma Transmission
    SUSAN NOH; Fiscal Year: 2004
    ..The sponsor has an active research program in vector borne disease has successfully mentored clinicians, graduate students, and post-doctoral fellows to research independence. ..
  47. A Plant-Derived, Multi-Component Tuberculosis Vaccine
    AMANDA WALMSLEY; Fiscal Year: 2004
    ..abstract_text> ..
  48. 3RD ANNUAL MUTANT MOUSE REGIONAL RESOURCE CENTER MEETING
    Stephen Barthold; Fiscal Year: 2003
    ....
  49. BACTERIAL MODULATION OF LUNG INFLAMMATORY RESPONSE
    Thomas Russo; Fiscal Year: 2004
    ..g. hemolysin) and bacterially induced host response elements in directly mediating the pathogenesis of lung injury. ..
  50. Ethanol, Tat and the Blood-brain barrier
    Kwang Kim; Fiscal Year: 2004
    ..e., nitric oxide and signaling pathways. The information derived from this proposal should enhance our understanding of the role of ethanol in HIV-1 neuropthogenesis. ..
  51. Immunotherapeutic strategies for breast cancer
    YVONNE J PATERSON; Fiscal Year: 2010
    ....
  52. Enhancing the immunogenicity of idiotypes for therapy of Non-Hodgkin's lymphoma
    Yvonne Paterson; Fiscal Year: 2006
    ..We will also have tested 3 possible adjuvants to enhance its delivery. This will set the stage for a Phase II proposal focused on preparations for entering clinical trials. [unreadable] [unreadable] [unreadable]..
  53. Genome-wide screening of E. coli for bacteremia
    Kwang Kim; Fiscal Year: 2007
    ..coli bacteremia should help in development of preventive measures such as vaccines against E. coli bacteremia. [unreadable] [unreadable] [unreadable]..
  54. Mucosal immune response to oral cholera vaccine Peru 15
    Firdausi Qadri; Fiscal Year: 2007
    ..cholerae. ..
  55. 5th Comparative Medicine Resource Center Director Mtg.
    Stephen Barthold; Fiscal Year: 2008
    ....
  56. Global GAS Vaccine Based On The M-Protein
    Michael Good; Fiscal Year: 2008
    ..abstract_text> ..
  57. Development of live Francisella tularensis vaccines
    Anders Sjostedt; Fiscal Year: 2009
    ..tularensis subsp. tularensis strains. To determine correlates of protection. ..
  58. Bacterial vector vaccine: Her-2/neu expressing tumors
    Yvonne Paterson; Fiscal Year: 2005
    ..This work will demonstrate the utility of the L. monocytogenes-based vaccines, thus setting the stage for further development of a breast cancer therapeutic that can be used in humans. ..
  59. HELICOBACTER DIAGNOSTIC ASSAYS FOR LABORATORY MICE
    Stephen Barthold; Fiscal Year: 2004
    ..abstract_text> ..
  60. B.abortus-based vaccine against viral hemorrhagic fevers
    Ramesh Vemulapalli; Fiscal Year: 2004
    ..abstract_text> ..